Fracture in clinical studies of tofacitinib in rheumatoid arthritis.

Hansen, Karen E; Mortezavi, Mahta; Nagy, Edward; Wang, Cunshan; Connell, Carol A; Radi, Zaher; Litman, Heather J; Adami, Giovanni; Rossini, Maurizio

Hansen, Karen E; Mortezavi, Mahta; Nagy, Edward; Wang, Cunshan; Connell, Carol A; Radi, Zaher; Litman, Heather J; Adami, Giovanni; Rossini, Maurizio.

Afiliação

Hansen KE; Division of Rheumatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Mortezavi M; Pfizer Inc., 235 E 42nd St., New York, NY 10017, USA.
Nagy E; Pfizer Ltd, Tadworth, UK.
Wang C; Pfizer Inc., Groton, CT, USA.
Connell CA; Pfizer Inc., Groton, CT, USA.
Radi Z; Pfizer Inc., Cambridge, MA, USA.
Litman HJ; CorEvitas, LLC, Waltham, MA, USA.
Adami G; Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy.
Rossini M; Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy.

Ther Adv Musculoskelet Dis ; 14: 1759720X221142346, 2022.

Article em En | MEDLINE | ID: mdl-36601090

Palavras-chave

JAK inhibitor; fracture; osteoporosis; rheumatoid arthritistofacitinib

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ther Adv Musculoskelet Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google